BAM
NVCR icon

Berkshire Asset Management’s NovoCure NVCR Stock Holding History

Berkshire Asset Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-15,000
Closed -$257K – 302
2024
Q3 		$257K Hold
15,000
– – 0.01% 249
2024
Q2 		$257K Buy
+15,000
New +$264K 0.01% 250

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Berkshire Asset Management's NVCR Position: Q4 2024 in Review

Berkshire Asset Management sold out of NovoCure (NVCR) in Q4 2024, closing a stake of 15,000 shares — an estimated $257K sold.

Berkshire Asset Management first reported a position in NVCR in Q2 2024 and held it in 2 quarters. The position peaked at $257K in Q3 2024. 238 funds tracked by Wall St. Rank hold NVCR as of Q4 2024.

  • Berkshire Asset Management reported no remaining NovoCure position as of Q4 2024 after selling out during the quarter.
  • Berkshire Asset Management sold 15,000 NovoCure shares in Q4 2024, an estimated $257K.
  • Berkshire Asset Management first reported a position in NovoCure in Q2 2024 and held it in 2 quarters.
  • Berkshire Asset Management's NovoCure position peaked at $257K in Q3 2024.
  • 238 funds tracked by Wall St. Rank held NovoCure as of Q4 2024.

Based on Berkshire Asset Management's 13F filing for Q4 2024, filed 7 Feb 2025.